Compare Davita Inc (DVA) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs VNET Group Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while VNET Group Inc trades at $5.26 (market cap $1.53B). The key difference: Davita Inc is far larger — about 7.4× VNET Group Inc's market cap, and Davita Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and VNET Group Inc for 16 Days on average.
| DVA | VNET | |
|---|---|---|
Market Cap | $11.28B | $1.53B |
Volume | 650,294 | 3,847,582 |
Sector | Health | Technology |
52-Week High | $240.96 | $14.03 |
52-Week Low | $103.87 | $5.13 |
Typical Hold Time | 113 Days | 16 Days |
Enterprise Value | $24.00B | $5.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
VNET trades at $5.39, near a 52-week low with a bearish technical signal. The company reported a net loss of $256.77 million in 2025, with revenue of $9.95 billion, and negative profit margins. Recent news highlights a strategic investment closing and volatile options activity. Cash flow remains positive due to financing activities, but high leverage and negative earnings pose challenges.
Outlook is mixed: analyst consensus is moderately bullish (62.5% buy ratings), but fundamentals show persistent losses and high debt. Key risks include execution on AI infrastructure demand and balance sheet strain. The stock's appeal hinges on turnaround execution amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
